C. Abeli

发表

Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, The Journal of antimicrobial chemotherapy.

Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2013, The Journal of antimicrobial chemotherapy.

Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures.

A. d’Arminio Monforte, V. Vullo, A. Antinori, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Weight Gain: A Possible Side Effect of All Antiretrovirals

L. Calza, A. Antinori, E. Ricci, 2017, Open forum infectious diseases.

Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, The Journal of antimicrobial chemotherapy.

Efficacy and safety of boosted and unboosted atazanavir‐containing antiretroviral regimens in real life: results from a multicentre cohort study

E. Gianelli, E. Ricci, P. Bonfanti, 2010, HIV medicine.

Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial

G. d’Ettorre, M. Colafigli, P. Vitiello, 2013, PloS one.

Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART

A. di Pietro, G. d’Ettorre, P. Vitiello, 2010, Journal of the International AIDS Society.

BK virus renal infection in a patient with the acquired immunodeficiency syndrome.

M. Nebuloni, L. Vago, R. Boldorini, 1999, Archives of pathology & laboratory medicine.

Observational Study on HIV-Infected Subjects Failing HAART Receiving Tenofovir Plus Didanosine as NRTI Backbone

A. d’Arminio Monforte, C. Mussini, P. Cicconi, 2007, Infection.

Outcome of a Second‐Line Protease Inhibitor‐Containing Regimen in Patients Failing or Intolerant of a First Highly Active Antiretroviral Therapy

A. Monforte, B. Castelnuovo, F. Adorni, 2000, Journal of acquired immune deficiency syndromes.

Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2018, The Journal of antimicrobial chemotherapy.

Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, BMC Public Health.

Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

Karin J. Metzner, Huldrych F. Günthard, E. Nicastri, 2014, The Journal of antimicrobial chemotherapy.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation

R. Maserati, P. Vitiello, F. Adorni, 2020, HIV research & clinical practice.

Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral‐experienced patients in advanced stages of HIV‐1 infection

M. Moroni, A. Monforte, M. Musicco, 1998, AIDS.

Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy.

A. Monforte, B. Castelnuovo, F. Adorni, 2000 .

Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2018, BMC Medicine.

CD4 cell counts at the third month of HAART may predict clinical failure.

A. d’Arminio Monforte, B. Castelnuovo, M. Musicco, 1999, AIDS.

First‐line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, A. Lazzarin, 2018, HIV medicine.

Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.